Works matching IS 10781552 AND DT 2018 AND VI 24 AND IP 6

Results: 11

Retraction notice.

Published in:: Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. NP1, doi. 10.1177/1078155218790179
Publication type:: Article

A response to the letter to the editor on “Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study”.

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 478, doi. 10.1177/1078155218782614

By:

Yeo, Denise;
Hossain, Ihtimam;
Lim, Soon Thye;
Farid, Mohamad;
Tao, Miriam;
Quek, Richard;
Tang, Tiffany;
Chan, Alexandre

Publication type:

Article

Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation?

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 477, doi. 10.1177/1078155218782593

By:

Ozaras, Resat;
Uraz, Suleyman;
Demirel, Aslihan;
Mete, Bilgul;
Tabak, Fehmi

Publication type:

Article

RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data.

Published in:

2018

By:

Leung, Henry W. C.;
Chan, Agnes L. F.;
Wang, Shyh-Yau

Publication type:

Correction Notice

Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 424, doi. 10.1177/1078155217719585

By:

Mitchell, Aaron;
Muluneh, Benyam;
Patel, Rachana;
Basch, Ethan

Publication type:

Article

Do checkpoint inhibitors rely on gut microbiota to fight cancer?

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 468, doi. 10.1177/1078155217715903

By:

Firwana, Belal;
Avaritt, Nathan;
Shields, Bradley;
Ravilla, Rahul;
Makhoul, Issam;
Hutchins, Laura;
Tackett, Alan J.;
Mahmoud, Fade

Publication type:

Article

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 412, doi. 10.1177/1078155217714859

By:

Bond, T. Christopher;
Szabo, Erika;
Gabriel, Susan;
Klastersky, Jean;
Tomey, Omar;
Mueller, Udo;
Schwartzberg, Lee;
Tang, Boxiong

Publication type:

Article

A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 453, doi. 10.1177/1078155217713363

By:

DasGupta, Ryan K.;
Marini, Bernard L.;
Rudoni, Joslyn;
Perissinotti, Anthony J.

Publication type:

Article

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 433, doi. 10.1177/1078155217710553

By:

Cuellar, Sandra;
Vozniak, Michael;
Rhodes, Jill;
Forcello, Nicholas;
Olszta, Daniel

Publication type:

Article

Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 403, doi. 10.1177/1078155217707335

By:

Kimura, Michio;
Usami, Eiseki;
Teramachi, Hitomi;
Yoshimura, Tomoaki

Publication type:

Article

How can we ensure value for money from expenditure on injectable cancer drugs?

Published in:

Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 6, p. 473, doi. 10.1177/1078155217706195

By:

Gilbar, Peter J.;
Chambers, Carole R.

Publication type:

Article